Diabetes
MSD DPP-4 inhibitor doesn’t increase CV risk in diabetes, heart patients
A major study of patients with type 2 diabetes and established cardiovascular disease has found that a DPP-4 inhibitor does not increase the risk for major adverse CV events, hospitalisation for heart failure or adverse events
Sanofi urges Govt co-funding of GP diabetes education
Sanofi is calling on the Federal Government to join with them to co-fund a GP diabetes education program aimed at reducing the condition’s growing financial burden on the Australian healthcare …
Sigma pharmacies in pilot diabetes program
Sigma’s Amcal and Guardian pharmacies have begun a national pilot program to test patients for diabetes in a more effective, convenient and systematic approach using new standard testing equipment in …
Low calorie liquid diet helps Type-2 diabetes
New research has found that a low calorie liquid formula diet may help treat and prevent the onset of Type-2 diabetes. Losing weight and following a restricted diet is already …
Price cut causes Invokana withdrawal
Janssen-Cilag has withdrawn a diabetes drug from the PBS after the Health Department requested a price cut of close to 40%
“Diabetes is a big and complex epidemic”
Community pharmacy is in a position to make significant inroads in the support and health outcomes of people living with diabetes, reports Leanne Philpott. Key Points: More than 1 million …